Refractory follicular B-cell non-Hodgkin's lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051115

This document outlines details of the previous Pharmaceutical Benefits Scheme (PBS) subsidised idelalisib for patients with Refractory follicular B-cell non-Hodgkin's lymphoma (FBHL).

For details on how to process a PBS Authority, see Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS).

Refractory follicular B-cell non-Hodgkin’s lymphoma quick reference

This table contains a quick reference for confirming what section/who administers the program, whether a PA is required and where it is processed.